Survanta 25 mg/mL (Beractant SUSPENSION) 25 mg/mL

Survanta 25 mg/mL is a suspension form of beractant, used for respiratory support in premature infants. This single-use vial is designed for endotracheal administration, providing essential lung surfactant therapy.

Strength

25 mg/mL

Pack Size

1 VIAL, SINGLE-USE in 1 CARTON (0074-1040-04) / 4 mL in 1 VIAL, SINGLE-USE

Manufacturer / TM Owner

AbbVie Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Survanta 25 mg/mL is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs lack sufficient surfactant, a substance that keeps the air sacs open. Survanta provides exogenous surfactant replacement, aiding in lung function and oxygenation. It is administered directly into the trachea to help infants breathe more easily.

Side Effects

Survanta 25 mg/mL works by replacing natural lung surfactant, which helps reduce surface tension in the alveoli. This action can improve lung compliance and gas exchange, making it easier for premature infants to breathe. The effects are typically observed soon after administration, supporting respiratory stability.

Precautions & Warnings

Survanta 25 mg/mL should be handled with care, ensuring proper aseptic techniques during administration. It is intended for single-use only and should not be reused. Always follow healthcare provider instructions for storage and administration to maintain product integrity and safety.

Avoid Interactions

Survanta 25 mg/mL may interact with other medications administered via the endotracheal route. It is important to consult with a healthcare provider to manage potential interactions. Additionally, ensure compatibility with any other respiratory support therapies being used concurrently.

Frequently Asked Questions

Survanta 25 mg/mL is used to treat respiratory distress syndrome in premature infants by providing exogenous surfactant replacement.

Survanta 25 mg/mL is administered directly into the trachea via the endotracheal route.

Survanta 25 mg/mL helps reduce surface tension in the lungs, improving lung compliance and gas exchange.

No, Survanta 25 mg/mL is intended for single-use only and should not be reused.

Potential interactions should be discussed with a healthcare provider to ensure safe concurrent use.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.